DYNE THERAPEUTICS INC

Dyne Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights

08 May 2025 04:30:00 By Nasdaq GlobeNewswire

Dyne Therapeutics Receives European Medicines Agency (EMA) Orphan Drug Designation for DYNE-251 in Duchenne Muscular Dystrophy

24 Apr 2025 04:30:00 By Nasdaq GlobeNewswire

Dyne Therapeutics Announces Chief Business Officer and Chief Scientific Officer Appointments

15 Apr 2025 04:30:00 By Nasdaq GlobeNewswire

Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

14 Apr 2025 13:30:00 By Nasdaq GlobeNewswire

Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Financial Officer

20 Mar 2025 13:30:00 By Nasdaq GlobeNewswire

Dyne Therapeutics Announces Appointment of Erick J. Lucera as Chief Financial Officer

20 Mar 2025 13:10:00 By Nasdaq GlobeNewswire

Dyne Therapeutics Announces New Long-Term Clinical Data from Phase 1/2 DELIVER Trial of DYNE-251 in Duchenne Muscular Dystrophy Demonstrating Unprecedented and Sustained Functional Improvement Through 18 Months

16 Mar 2025 16:00:00 By Nasdaq GlobeNewswire

Dyne Therapeutics to Present at Stifel 2025 Virtual CNS Forum

11 Mar 2025 04:30:00 By Nasdaq GlobeNewswire

Dyne Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

27 Feb 2025 04:30:00 By Nasdaq GlobeNewswire

Dyne Therapeutics Announces Upcoming Presentations at the 2025 MDA Clinical & Scientific Conference

14 Feb 2025 13:05:00 By Nasdaq GlobeNewswire

Dyne Therapeutics to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference

03 Feb 2025 04:30:00 By Nasdaq GlobeNewswire

Dyne Therapeutics Receives FDA Fast Track Designation for DYNE-101 for the Treatment of Myotonic Dystrophy Type 1

21 Jan 2025 04:30:00 By Nasdaq GlobeNewswire

Dyne Therapeutics Reports New Clinical Data Showing Compelling Impact on Multiple Measures of Myotonic Dystrophy Type 1 (DM1); Dyne Plans to Initiate Registrational Expansion Cohort to Support Potential Submission for U.S. Accelerated Approval for DYNE-101 in DM1 in H1 2026

10 Jan 2025 03:30:00 By Nasdaq GlobeNewswire

Dyne Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference

09 Jan 2025 04:30:04 By Nasdaq GlobeNewswire

Dyne Therapeutics to Host Investor Conference Call and Webcast to Review New Clinical Data from the ACHIEVE Trial Friday, January 10 at 8:00 a.m. ET

08 Jan 2025 13:05:29 By Nasdaq GlobeNewswire

Dyne Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

12 Nov 2024 04:30:00 By Nasdaq GlobeNewswire

Dyne Therapeutics to Present at Upcoming Investor Conferences

07 Nov 2024 13:15:00 By Nasdaq GlobeNewswire

Dyne Therapeutics Presents Data at World Muscle Society Congress Highlighting Promise of FORCE™ Platform to Address Underlying Causes of Neuromuscular Diseases

09 Oct 2024 04:30:00 By Nasdaq GlobeNewswire

Dyne Therapeutics to Present at Chardan’s 8th Annual Genetic Medicines Conference

23 Sep 2024 05:56:28 By Nasdaq GlobeNewswire

Dyne Therapeutics Announces Key Leadership Appointments

03 Sep 2024 03:31:00 By Nasdaq GlobeNewswire